Please ensure Javascript is enabled for purposes of website accessibility

Why FibroGen Stock Is Crashing Today

By Keith Speights - Apr 7, 2021 at 11:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company disclosed a bombshell related to its safety results for lead candidate roxadustat.

What happened

Shares of FibroGen (FGEN 0.35%) were crashing 37.8% lower as of 10:45 a.m. EDT on Wednesday. The huge drop came after the company announced a stunning revelation following the market close on Tuesday. FibroGen revealed that some previously disclosed safety analyses from a late-stage study of roxadustat in treating anemia of chronic kidney disease (CKD) were incorrect.

So what

The big bombshell in FibroGen's announcement is that the company can no longer claim that roxadustat reduces the risk of major adverse cardiovascular events (MACE) compared to erythropoiesis-stimulating agent epoetin alfa. This undercuts something the company has maintained for a couple of years.

The timing couldn't have been much worse. The news broke as FibroGen was preparing for an upcoming U.S. Food and Drug Administration (FDA) advisory committee meeting set to review the regulatory filing for roxadustat.

Man wearing a suit looking at a red line trending down

Image source: Getty Images.

FibroGen maintains that there wasn't any change to the underlying data of the late-stage study of roxadustat. The company also said that the efficacy analysis from the study wasn't impacted. However, stratification factors were changed that inflated how much the drug reduced the risks of MACE in patients. 

This isn't just a public relations fiasco for FibroGen. It could lower the chances that roxadustat wins FDA approval. It could also impact FibroGen's partnership with AstraZeneca

Now what

FibroGen stated that it has "begun a comprehensive internal review to ensure such issues do not occur in the future." The results from that internal review will likely be important in how quickly the company can begin to rebuild credibility -- and for the biotech stock to recover.

An even more critical even is coming up soon. The FDA advisory committee is tentatively scheduled to meet on July 15 to review the regulatory filing for roxadustat.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

FibroGen, Inc. Stock Quote
FibroGen, Inc.
$8.60 (0.35%) $0.03
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.21 (2.59%) $1.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.